Introduction {#jde14501-sec-0001}
============

Atopic dermatitis (AD) is a chronic relapsing--remitting skin disease characterized by pruritus and skin inflammation.[1](#jde14501-bib-0001){ref-type="ref"} Interactions among skin barrier dysfunction, immune abnormalities and infectious/environmental agents are thought to play roles in the development of AD, although the precise disease pathogenesis is not fully elucidated.[1](#jde14501-bib-0001){ref-type="ref"}

Atopic dermatitis usually appears in infancy and childhood (\~85% of cases), and more than two‐thirds of pediatric patients with AD outgrow the condition before adolescence.[2](#jde14501-bib-0002){ref-type="ref"} However, approximately 1--3% of adults are also affected.[3](#jde14501-bib-0003){ref-type="ref"} The chronic nature of AD and the requirement for the frequent application of emollients and topical medications mean that its burden is high for patients and the health‐care system.

The main goals of therapy in patients with AD include relieving pruritus, improving skin barrier function, reducing inflammation and preventing flares.[1](#jde14501-bib-0001){ref-type="ref"} Although preventing disease flares requires long‐term management, it has also been suggested that achieving remission with initial therapy may have a "disease‐modifying" effect and therefore play an important role in the long‐term management of AD.[4](#jde14501-bib-0004){ref-type="ref"} The effective treatment of AD is important not only for improving symptoms and quality of life but also for preventing the development of chronic or severe symptoms. The use of topical anti‐inflammatory agents in pediatric patients with AD has been described as an important, potentially disease‐modifying strategy.[5](#jde14501-bib-0005){ref-type="ref"} Therefore, the ideal first‐line pharmacological agents for the treatment of AD should have an excellent safety/tolerability profile as well as reliable anti‐inflammatory efficacy.

Currently recommended first‐line treatments include topical corticosteroids (TCS) and tacrolimus ointment (TAC‐O).[6](#jde14501-bib-0006){ref-type="ref"}, [7](#jde14501-bib-0007){ref-type="ref"}, [8](#jde14501-bib-0008){ref-type="ref"} Although TCS have potent anti‐inflammatory activity in the maintenance treatment as well as in the crisis intervention,[9](#jde14501-bib-0009){ref-type="ref"}, [10](#jde14501-bib-0010){ref-type="ref"} their long‐term use is known to be associated with cutaneous adverse events such as skin atrophy.[11](#jde14501-bib-0011){ref-type="ref"}, [12](#jde14501-bib-0012){ref-type="ref"}, [13](#jde14501-bib-0013){ref-type="ref"} The occurrence of these side‐effects can decrease patient adherence to topical treatments, sometimes leading to the cessation of TCS.[14](#jde14501-bib-0014){ref-type="ref"}, [15](#jde14501-bib-0015){ref-type="ref"}

The mechanism of action of TAC‐O differs from those of TCS.[16](#jde14501-bib-0016){ref-type="ref"} Topical tacrolimus inhibits the activation of pro‐inflammatory cells such as T lymphocytes and mast cells[17](#jde14501-bib-0017){ref-type="ref"}, [18](#jde14501-bib-0018){ref-type="ref"} and prevents the progression of cytokine‐driven inflammation (Fig. [1](#jde14501-fig-0001){ref-type="fig"}).

![Mechanism of action for tacrolimus. FKBP,FK506‐binding protein; NFAT, nuclear factor of activated T cells; PKC, protein kinase C; PLC, phospholipase C; TK, tyrosine kinase.](JDE-45-936-g001){#jde14501-fig-0001}

In 2003, the Japanese labeling for TAC‐O was updated to include a warning about a possible risk of lymphoma and skin cancer. The US Food and Drug Administration (FDA) followed suit in 2006, issuing a boxed warning requirement for the labeling for two topical calcineurin inhibitors, namely tacrolimus and pimecrolimus, and highlighting a possible risk of lymphoma and skin cancer secondary to these agents' effects on the immune system. The FDA\'s boxed warning and Japanese labeling warning emphasize this theoretical risk by stating that health‐care providers and patients should be aware of the long‐term risks of these products (i.e. their potential to cause cancer) and that the use of these agents in children under 2 years of age is not recommended.[19](#jde14501-bib-0019){ref-type="ref"}, [20](#jde14501-bib-0020){ref-type="ref"} Consequently, the European Medicines Agency and many other regulatory authorities took the same actions to increase health professionals' awareness of these risks associated with topical calcineurin inhibitors.

Tacrolimus ointment has been available in Japan for more than 15 years, including the 10 years since the FDA approved the labeling update to include the boxed warning about its carcinogenic potential. Therefore, a review of the safety data of TAC‐O, including its carcinogenic potential, as well as its benefits in patients with AD would be useful at this point. This review of the available published work concludes with a consensus opinion from Japanese pediatric, dermatological and allergology experts.

Clinical Efficacy of Tacrolimus in AD {#jde14501-sec-0002}
=====================================

Several systematic reviews and meta‐analyses have summarized the clinical data on TAC‐O in AD. Based on the combined results of 19 studies of calcineurin inhibitors (TAC‐O or pimecrolimus) in patients with AD, TAC‐O 0.03% and 0.1% were more effective than mild TCS and had similar efficacy to that of medium‐potency TCS.[21](#jde14501-bib-0021){ref-type="ref"} In a more recent analysis of calcineurin inhibitor studies, the overall efficacy of TAC‐O 0.1% was at least as good as that of medium‐potency TCS, although TAC‐O 0.03% was less effective.[22](#jde14501-bib-0022){ref-type="ref"} TAC‐O 0.1% was demonstrated to have similar efficacy to those of medium‐ and high‐potency TCS in other analyses.[23](#jde14501-bib-0023){ref-type="ref"}, [24](#jde14501-bib-0024){ref-type="ref"} In a meta‐analysis focusing specifically on studies in pediatric patients with AD, there were no statistically significant differences in efficacy between TAC‐O 0.03% and 0.1%, and response rates with TAC‐O were higher than those for patients with AD treated with hydrocortisone 1% or pimecrolimus 1% cream.[25](#jde14501-bib-0025){ref-type="ref"} The anti‐inflammatory activity of TAC‐O 0.03% has been defined as equipotent to medium‐ to high‐potency TCS.[26](#jde14501-bib-0026){ref-type="ref"}, [27](#jde14501-bib-0027){ref-type="ref"}, [28](#jde14501-bib-0028){ref-type="ref"}

One of the important effects of TAC‐O is its ability to relieve pruritus.[29](#jde14501-bib-0029){ref-type="ref"}, [30](#jde14501-bib-0030){ref-type="ref"} This is thought to be attributed to desensitization of the cutaneous sensory neurons.[31](#jde14501-bib-0031){ref-type="ref"}, [32](#jde14501-bib-0032){ref-type="ref"} TAC‐O has also been shown to decrease neuropeptide levels in the lesional skin of patients with AD, suggesting that interference with neurogenic tissue inflammation is a possible mechanism for the beneficial effects of TAC‐O.[33](#jde14501-bib-0033){ref-type="ref"} Data from an *in vitro* study of human mast cells suggest that the subsets of chemokines inhibited by tacrolimus differ from those inhibited by corticosteroids,[34](#jde14501-bib-0034){ref-type="ref"} raising the possibility that combination treatment may be more effective than either individual agent alone and highlighting the importance of individualizing the choice of therapeutic agents in patients with AD.

The effective treatment of AD with TAC‐O has been associated with improved quality of life both in pediatric[35](#jde14501-bib-0035){ref-type="ref"}, [36](#jde14501-bib-0036){ref-type="ref"} and adult patients.[37](#jde14501-bib-0037){ref-type="ref"} In a study of 30 pediatric patients with AD, significant improvements in overall quality of life obtained in the first week of therapy maintained throughout the 4‐week study period, as well as the improvements in erythema and papulation scores, pruritus and sleeplessness.[35](#jde14501-bib-0035){ref-type="ref"} In adult patients with AD, data from a double‐blind randomized controlled trial (RCT) comparing 6‐month treatment with TAC‐O 0.1% and TCS showed that TAC‐O was associated with a clinically significant improvement of quality of life that was sustained throughout the treatment period and that quality of life improvements with TAC‐O were significantly greater than those with TCS.[37](#jde14501-bib-0037){ref-type="ref"}

The conventional treatment approach to managing AD has consisted of a combination of daily application of emollients combined with the application of topical anti‐inflammatory agents (TCS or topical calcineurin inhibitors) as required to manage visible skin lesions. More recently, a proactive approach to the long‐term management of AD has been investigated. This approach includes intensive topical anti‐inflammatory treatment of visible lesions until clearance has been obtained followed by the intermittent application of low‐dose anti‐inflammatory agents to these areas to prevent disease flares.[9](#jde14501-bib-0009){ref-type="ref"}, [10](#jde14501-bib-0010){ref-type="ref"}, [38](#jde14501-bib-0038){ref-type="ref"} This approach is based on evidence that although skin may appear normal after the resolution of an AD episode, a number of defects persist, including impaired barrier function and subclinical inflammation.[39](#jde14501-bib-0039){ref-type="ref"}, [40](#jde14501-bib-0040){ref-type="ref"} Proactive treatment with TAC‐O has been shown to prevent, delay and reduce the occurrence of disease exacerbations in adults and children with AD.[38](#jde14501-bib-0038){ref-type="ref"}, [41](#jde14501-bib-0041){ref-type="ref"}, [42](#jde14501-bib-0042){ref-type="ref"}, [43](#jde14501-bib-0043){ref-type="ref"}, [44](#jde14501-bib-0044){ref-type="ref"} Long‐term TAC‐O treatment may also help attenuate the progression of AD to allergic rhinitis or bronchial asthma, the so‐called "atopic march".[45](#jde14501-bib-0045){ref-type="ref"}

Clinical Safety of Tacrolimus in AD {#jde14501-sec-0003}
===================================

The overall tolerability profile of TAC‐O is favorable and serious adverse events are quite rare. The most common adverse events in adults and children are application site reactions including burning and pruritus.[46](#jde14501-bib-0046){ref-type="ref"}, [47](#jde14501-bib-0047){ref-type="ref"}, [48](#jde14501-bib-0048){ref-type="ref"}, [49](#jde14501-bib-0049){ref-type="ref"}, [50](#jde14501-bib-0050){ref-type="ref"}, [51](#jde14501-bib-0051){ref-type="ref"}, [52](#jde14501-bib-0052){ref-type="ref"} However, these adverse events are usually transient and decrease in severity after the first few days of treatment. Local irritation associated with TAC‐O is thought to occur through the activation of TRPV1 nociceptors distributed throughout sensory neuron terminals, which is a known mechanism of action of the drug.[31](#jde14501-bib-0031){ref-type="ref"} The attenuation of skin irritation over time has a physiological basis because repeated applications have been shown to desensitize subsequent sensory neuronal activation[31](#jde14501-bib-0031){ref-type="ref"} and eventually nullify the irritant response.[24](#jde14501-bib-0024){ref-type="ref"}, [46](#jde14501-bib-0046){ref-type="ref"}

Tacrolimus ointment has a potential to increase the risk of cutaneous infections due to its immunosuppressive effect. However, several clinical trials have shown similar frequencies of cutaneous infections in patients treated with TAC‐O and control patients treated with vehicle.[53](#jde14501-bib-0053){ref-type="ref"} A retrospective study including 388 Japanese adult AD patients with total treatment periods ranging 5--17 years revealed that the overall incidence of herpes simplex virus infection during treatment with TAC‐O and TCS did not exceed the incidence in patients with AD.[54](#jde14501-bib-0054){ref-type="ref"} Moreover, it has also been reported that tacrolimus actually reduces the staphylococcal colonization of AD lesions, possibly as a result of reduced skin inflammation and improved skin barrier function.[55](#jde14501-bib-0055){ref-type="ref"} This restoration of skin barrier function has been documented in studies specifically focusing on this issue, showing recovery of the lamellar structure of the skin,[56](#jde14501-bib-0056){ref-type="ref"}, [57](#jde14501-bib-0057){ref-type="ref"} and is in contrast to the impairment of skin barrier function associated with long‐term TCS use.

Black Box and Japanese Labeling Safety Risk of Skin Cancer or Lymphoma {#jde14501-sec-0004}
======================================================================

There is currently no strong evidence supporting the boxed warning requirement issued by the US FDA and the warning of Japanese labeling regarding the use of TAC‐O in the treatment of AD. These warnings themselves actually state that a causal relationship between malignancy and topical calcineurin inhibitor use has not been established.[20](#jde14501-bib-0020){ref-type="ref"}

The risk of malignancy in chronically immunosuppressed human organ transplant recipients has been well documented.[58](#jde14501-bib-0058){ref-type="ref"}, [59](#jde14501-bib-0059){ref-type="ref"} For liver transplantation, the p.o. or i.v. administration of immunosuppressants, such as calcineurin inhibitors including tacrolimus, has been reported to be associated with the development of malignancy and lymphoma.[60](#jde14501-bib-0060){ref-type="ref"}, [61](#jde14501-bib-0061){ref-type="ref"}, [62](#jde14501-bib-0062){ref-type="ref"}, [63](#jde14501-bib-0063){ref-type="ref"}, [64](#jde14501-bib-0064){ref-type="ref"} Systemic immunosuppression is thought to be a mechanism underlying the development of cancer in human organ transplant recipients receiving systemic treatment with a calcineurin inhibitor.[65](#jde14501-bib-0065){ref-type="ref"}, [66](#jde14501-bib-0066){ref-type="ref"} In both animals and humans receiving oral immunosuppressants, the extent of systemic drug exposure resulting in systemic immune suppression is significantly greater than that after use of TAC‐O.[19](#jde14501-bib-0019){ref-type="ref"} In fact, systemic drug exposure after TAC‐O administration is absent or minimal,[47](#jde14501-bib-0047){ref-type="ref"}, [67](#jde14501-bib-0067){ref-type="ref"}, [68](#jde14501-bib-0068){ref-type="ref"} and no immunosuppression was observed after 1--4 years' intermittent treatment with TAC‐O.[69](#jde14501-bib-0069){ref-type="ref"}

Skin malignancies and lymphoma have been reported in animals after topical calcineurin inhibitor treatment. The carcinogenic effect of topical tacrolimus was investigated using a mouse model and some tumor‐promoting effects were noted.[70](#jde14501-bib-0070){ref-type="ref"} Mice naturally have thinner skin and more fragile skin barriers than humans. In the carcinogenicity study using mice, TAC‐O was applied to a large area for 2 years. This resulted in much higher systemic drug concentrations than those in patients during routine topical treatment of AD at recommended drug doses.[71](#jde14501-bib-0071){ref-type="ref"} Data from a study using an initiation/promotion mouse model of cutaneous carcinogenesis designed to investigate the carcinogenic effects of TAC‐O showed that TAC‐O 0.03% or 0.1% actually had an inhibitory effect on skin neoplasms.[72](#jde14501-bib-0072){ref-type="ref"} This was thought to be secondary to the inhibition of 12‐*O*‐tetradecanoylphorbol‐13‐acetate promotion without any immunosuppressive effects. Furthermore, animal studies showing the development of lymphoma after the application of topical tacrolimus or pimecrolimus, another topical calcineurin inhibitor available in the world so far, used drugs dissolved in ethanol at concentrations 26 and 47 times the maximum recommended human dose, respectively.[73](#jde14501-bib-0073){ref-type="ref"}

Cases of cutaneous cancer or lymphoma have been observed following use of topical calcineurin inhibitors. Several published studies have investigated the incidence of cancers, including lymphoma, in patients with AD treated with TAC‐O.[22](#jde14501-bib-0022){ref-type="ref"}, [69](#jde14501-bib-0069){ref-type="ref"}, [74](#jde14501-bib-0074){ref-type="ref"}, [75](#jde14501-bib-0075){ref-type="ref"}, [76](#jde14501-bib-0076){ref-type="ref"}, [77](#jde14501-bib-0077){ref-type="ref"}, [78](#jde14501-bib-0078){ref-type="ref"}, [79](#jde14501-bib-0079){ref-type="ref"}, [80](#jde14501-bib-0080){ref-type="ref"} Looking specifically at skin cancers, a case--control study was conducted using a questionnaire in 3074 evaluable adults with AD.[74](#jde14501-bib-0074){ref-type="ref"} In this study, topical calcineurin inhibitor exposure was not associated with an increased risk of developing non‐melanoma skin cancer; subjects who had used TAC‐O had the lowest rate of non‐melanoma skin cancer versus those treated with pimecrolimus or those who did not receive a topical calcineurin inhibitor. An evaluation of malignancy risk related to AD and the use of topical calcineurin inhibitors from published work found no evidence of association with topical calcineurin inhibitors in melanoma or non‐melanoma skin cancer, although the inference that calcineurin inhibitors do not cause malignancy was not derived for overall malignancies.[75](#jde14501-bib-0075){ref-type="ref"}

A large case--control study investigated the relationship between topical calcineurin inhibitor use and lymphoma.[76](#jde14501-bib-0076){ref-type="ref"} On adjusted analysis, the odds ratio (OR) for lymphoma development was 0.8 (95% confidence interval \[CI\], 0.4--1.7) in patients treated with TAC‐O versus 2.4 (95% CI, 1.5--3.8) for those with severe AD regardless of topical treatments, suggesting that disease severity is a more potent risk factor for lymphoma than TAC‐O use. AD severity indicated by referral to a dermatologist was also associated with increased lymphoma risk in a similar study conducted in the UK (OR, 3.72; 95% CI, 1.40--9.87); lymphoma risk was also increased in users of high‐strength TCS (OR, 1.80; 95% CI, 1.54--2.11) but not in those of topical calcineurin inhibitors, in whom no cases of lymphoma occurred during the study period.[77](#jde14501-bib-0077){ref-type="ref"} The results of a meta‐analysis also support an association of both AD severity and high‐strength TCS with increased lymphoma risk, whereas the majority of included studies showed no relationship between topical calcineurin inhibitor use and lymphoma.[78](#jde14501-bib-0078){ref-type="ref"}

A large retrospective cohort observational study based on an integrated health‐care insurance database (follow‐up duration, 2--2.5 years) has shown an increased risk for cutaneous T‐cell lymphoma in eczema patients with the use of TAC‐O, but not pimecrolimus, compared with patients who were not exposed to topical calcineurin inhibitors.[79](#jde14501-bib-0079){ref-type="ref"} There was an increase in the risk of T‐cell lymphoma in patients treated with TAC‐O at higher concentrations and cumulative doses, but the difference did not reach statistical significance. On the other hand, when compared with the general population, an increased risk for cutaneous lymphoma with the use of TAC‐O, pimecrolimus and TCS has been reported, but needed longer‐term studies for the conclusion.[80](#jde14501-bib-0080){ref-type="ref"}

Based on the results of these investigations, the risk for malignancies associated with topical calcineurin inhibitors is best addressed by the systematic review on the efficacy, safety and cost‐effectiveness of topical calcineurin inhibitors in AD.[22](#jde14501-bib-0022){ref-type="ref"} It has been suggested that the lymphoma diagnosed after treatment with topical calcineurin inhibitor was pre‐existing cutaneous T‐cell lymphoma, which often initially presents as an eczematous rash and may be misdiagnosed as AD, leading to overestimation of the association between topical calcineurin inhibitors and lymphoma.[71](#jde14501-bib-0071){ref-type="ref"}, [75](#jde14501-bib-0075){ref-type="ref"}, [79](#jde14501-bib-0079){ref-type="ref"} In a Japanese postmarketing surveillance study of pediatric patients with AD being treated with TAC‐O 0.03%, no cases of treatment‐related malignancy have been identified over 7 years of a planned 10‐year follow up.[81](#jde14501-bib-0081){ref-type="ref"}

Discussion {#jde14501-sec-0005}
==========

Atopic dermatitis has a relapsing--remitting course in which periods of relative remission alternate with periods of acute worsening, namely disease flares. The proactive management strategy includes scheduled regular intermittent use of topical anti‐inflammatory agents along with regular use of emollients to prevent AD flares. This requires long‐term use of TCS or topical calcineurin inhibitors. The use of TCS in this setting is limited by its unfavorable effects on skin barrier function.[11](#jde14501-bib-0011){ref-type="ref"}, [12](#jde14501-bib-0012){ref-type="ref"}, [13](#jde14501-bib-0013){ref-type="ref"} Therefore, TAC‐O may be a preferred option as maintenance treatment for AD in remission.

Although the US FDA issued a boxed warning requirement in 2006, cautioning about an increased risk of skin cancer and lymphoma with the use of topical calcineurin inhibitors including TAC‐O, there is no robust evidence to support this association from clinical trials and postmarketing surveillance studies. A report by the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology stated that current data based on use in nearly 7 million individuals do not provide any evidence of an increased incidence of lymphoma with short‐term or intermittent application of topical TAC‐O or topical pimecrolimus.[73](#jde14501-bib-0073){ref-type="ref"} In addition, the American Academy of Dermatology Association Task Force conference failed to find any causal proof of a relationship between topical calcineurin inhibitor use and skin cancer or lymphoma, and it also suggested that systemic immunosuppression after short‐term or intermittent long‐term use of these agents was an unlikely mechanism for cancer risk.[82](#jde14501-bib-0082){ref-type="ref"}

Furthermore, it has been reported that combination therapy of narrowband ultraviolet B (NBUVB) and topical calcineurin inhibitors including TAC‐O showed better responses in repigmentation of vitiligo affecting the face and the neck than NB‐UVB monotherapy,[83](#jde14501-bib-0083){ref-type="ref"} and there are a series of reports on double‐blind RCT regarding those combination therapies.[84](#jde14501-bib-0084){ref-type="ref"}, [85](#jde14501-bib-0085){ref-type="ref"}, [86](#jde14501-bib-0086){ref-type="ref"}, [87](#jde14501-bib-0087){ref-type="ref"}, [88](#jde14501-bib-0088){ref-type="ref"} Although the combination therapy is contraindicated in Japanese guidelines for the diagnosis and treatment of vitiligo,[89](#jde14501-bib-0089){ref-type="ref"} it is stated in the European Dermatology Forum consensus guidelines for the management of vitiligo, that there is good evidence for the efficacy of combination of NBUVB and topical calcineurin inhibitors and that it provides better results than the two treatments used alone.[90](#jde14501-bib-0090){ref-type="ref"} The European guidelines also mention that accumulated data suggest that the combination therapy may be effective and safe, although long‐term data on carcinogenicity are still lacking.

The presence of the boxed US FDA warning for topical calcineurin inhibitors and the warning in Japanese labeling for TAC‐O has had a number of negative consequences. Prescription rates decreased and some health‐care payers introduced additional hurdles for physicians and patients such as health‐care payment restrictions, making it more difficult to access these agents.[19](#jde14501-bib-0019){ref-type="ref"} The results of an anonymous survey of US dermatology conference attendees in 2007 (after the boxed warning was issued) showed that changes to therapies based on the warning were associated with a loss of disease control in some patients whose conditions were previously well controlled using topical calcineurin inhibitors.[91](#jde14501-bib-0091){ref-type="ref"} In addition, the therapies chosen to replace topical calcineurin inhibitors, including TCS, systemic corticosteroids and other systemic immunosuppressants, often had worse tolerability profiles and risk--benefit ratios than the treatment they replaced. Some physicians also felt that the warnings would be a deterrent to participation in future clinical trials, limiting the ability to accurately determine the real risk of malignancy during long‐term use of topical calcineurin inhibitors.[92](#jde14501-bib-0092){ref-type="ref"}

Several investigators pointed out that "topical corticosteroid phobia" encompasses concerns, fears, worries, anxiety, sorrow and doubts about TCS use. The term "topical corticosteroid phobia" was suggested to be a misnomer because the concerns have a rational background of available evidence.[93](#jde14501-bib-0093){ref-type="ref"}, [94](#jde14501-bib-0094){ref-type="ref"}, [95](#jde14501-bib-0095){ref-type="ref"} Instead, it has been proposed to use the term "corticosteroid concerns" rather than "corticosteroid phobia" in future discussions.[95](#jde14501-bib-0095){ref-type="ref"} On the other hand, in the case of topical calcineurin inhibitors, we believe that we should use the term "topical calcineurin inhibitor phobia" rather than "topical calcineurin inhibitor concerns" for the warning on malignancies due to the lack of established scientific evidence.

Review Recommendations {#jde14501-sec-0006}
======================

Overall, the published data summarized above suggest that the warning included in the current Japanese labeling for TAC‐O is not based on the reports of malignancies whose causal relationship to the drug has been determined. As a result, the warning does not appear justified in the context of optimal clinical use at currently approved doses, as was stated by Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.[73](#jde14501-bib-0073){ref-type="ref"} Therefore, we conclude that TAC‐O is a safe and effective option for the treatment of AD in both children and adults.

We join these other experts in stating that the current warning of the Japanese labeling for TAC‐O is not appropriate based on available scientific evidence and that the boxed US FDA warning should also be reconsidered.[73](#jde14501-bib-0073){ref-type="ref"}, [82](#jde14501-bib-0082){ref-type="ref"}, [96](#jde14501-bib-0096){ref-type="ref"} We believe that this would be the best approach to ensuring that all patients with AD receive the most appropriate and effective treatment.
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